425: TuHURA Biosciences Announces Abstracts Accepted for Poster Presentation at 2025 AACR Annual Meeting

TuHURA Biosciences announces that abstracts highlighting Kineta Inc.'s KVA12123 antibody and Moffitt Cancer Center scientists' examination of IFx-Hu2.0 therapy mechanisms have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Summary

• TuHURA Biosciences, a Phase 3 immune-oncology company, announced that abstracts related to Kineta's KVA12123 antibody and TuHURA's IFx-Hu2.0 therapy have been accepted for poster presentation at the AACR Annual Meeting 2025.
• The AACR Annual Meeting will take place from April 25-30, 2025, in Chicago, IL.
• One abstract highlights initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors.
• Another abstract examines mechanistic insights into IFx-Hu2.0 responses in the first human trial after prior anti-PD-1 therapy failure.
• TuHURA is in the process of acquiring Kineta, including the rights to the KVA12123 antibody, in a merger transaction expected to close in Q2 2025.
• TuHURA is preparing to initiate a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda for advanced or metastatic Merkel Cell Carcinoma.

Sentiment

Score: 7

Explanation: The announcement is positive, highlighting upcoming presentations and progress in clinical development. The sentiment is moderately positive due to the inherent risks and uncertainties associated with clinical trials and mergers.

Positives

• Acceptance of abstracts at the AACR Annual Meeting provides visibility for TuHURA's and Kineta's research.
• The planned Phase 3 trial of IFx-2.0 represents a significant step in its development.
• The acquisition of Kineta expands TuHURA's pipeline with the addition of KVA12123.

Risks

• The merger with Kineta is subject to funding and other closing conditions, which may not be satisfied.
• The Phase 3 trial of IFx-2.0 may not be successful.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

TuHURA anticipates closing the acquisition of Kineta in Q2 2025 and initiating a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda for advanced or metastatic Merkel Cell Carcinoma.

Industry Context

The announcement highlights TuHURA's focus on developing novel technologies to overcome resistance to cancer immunotherapy, a significant challenge in the field. The company's approach of targeting both innate and adaptive immunity aligns with current trends in immuno-oncology research.

Comparison to Industry Standards

• TuHURA's focus on overcoming resistance to checkpoint inhibitors aligns with the strategies of companies like Bristol-Myers Squibb and Merck, which are also developing combination therapies to improve patient outcomes.
• Kineta's KVA12123, an anti-VISTA antibody, is similar to other VISTA inhibitors in development by companies like Jounce Therapeutics, which are being explored as potential cancer immunotherapies.
• The planned Phase 3 trial of IFx-2.0 with Keytruda for Merkel Cell Carcinoma is comparable to other registration trials evaluating combination therapies in this indication.

Stakeholder Impact

• Shareholders may react positively to the news of upcoming presentations and progress in clinical development.
• Employees may be motivated by the company's advancements and future plans.
• Patients with cancer may benefit from the development of new therapies.

Next Steps

• TuHURA will present abstracts at the AACR Annual Meeting 2025.
• TuHURA will work to satisfy the closing conditions for the acquisition of Kineta.
• TuHURA will initiate a Phase 3 registration trial of IFx-2.0 with Keytruda for Merkel Cell Carcinoma.

Key Dates

Keywords

TuHURA Biosciences, Kineta, KVA12123, IFx-Hu2.0, AACR Annual Meeting, Immuno-oncology, Phase 3 trial, Merger, Antibody, Pembrolizumab, Merkel Cell Carcinoma